FN2 Earnings Intelligence

BioMarin Pharmaceutical Inc. earnings overview

Latest BioMarin Pharmaceutical Inc. (BMRN) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportBioMarin Pharmaceutical Inc. reports Monday, Feb 22, 2027 · After market closeConsensus EPS $1.67 · consensus revenue $1.14B
BMRN FY2026 Q3 · Calendar Q4 2026

BioMarin Pharmaceutical Inc.

The quarter supports a view that BioMarin’s commercial portfolio is growing, while the lowered outlook shows that order timing and geopolitical disruption can outweigh strong reported demand in the near term. The durability of growth depends on execution across the expanded portfolio and pipeline, as well as resolution of customer timing pressures.

EPS surprise+376.0%
Market move-1.8%

Get the BMRN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.